Clinical Trial Update: Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer [Phase 3]

View source ↗

Summary

A Phase 3 study comparing SHR-1210 to investigator's choice chemotherapy in advanced esophageal cancer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• SHR-1210 (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Esophageal Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2024-01-22